Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur

EVERSANA’s Value and Evidence (V&E) team grew their global Health Economics & Outcomes Research (HEOR) leadership footprint in early 2024 with the addition of Monique Martin, Pamela Vo and Deepika Thakur, showcasing EVERSANA’s growing global life sciences commercialization launch expertise.  

EVERSANA’s Value & Evidence team of ~150 seasoned 卫生经济学和成果研究 researchers and industry experts are focused on improving healthcare outcomes. We work throughout a product’s life cycle from early-stage strategic planning, through launch, to post-launch support. We collaborate with clients to develop a Value & Evidence Platform that powers evidence development strategies, product value propositions, reimbursement submissions, payer marketing and peer-reviewed publications. Learn more.  

---

Nicole Ferko, General Manager, Value & Evidence, EVERSANA

Why was it necessary to expand the global footprint of EVERSANA’s HEOR team?

Our team has strong methodological expertise to support health technology assessment (HTA) globally, which is a fundamental requirement for reimbursement in many regions. Adding a European footprint in the HEOR space will increase diversity in our HTA experiences and provide access to localized experts. Our imperative is to continually grow, so that we expand opportunities for our incredible team members and so that we can provide the full spectrum of HEOR services our clients need to succeed. Expansion of our footprint, and the addition of incredible senior talent, are necessary steps to ensure this imperative is met. 

What does EVERSANA’s growing HEOR expertise and services mean to the life sciences industry?

The provision of HEOR services is, quite simply, an extremely niche market; one that requires unique methodological training and expertise. Through expansion of our footprint and senior talent pool, we are more readily able to provide solutions to the most complex of evidence and reimbursement challenges. We can do this through one large, diverse and integrated team of value and evidence experts, instead of our clients having to source siloed solutions. Ultimately, this expansion will help to achieve improved access to lifechanging healthcare therapies for patients worldwide.  

Monique Martin, SVP, Value & Evidence, Europe, Drives Actionable Impact from London, UK

What expertise do you bring to the team?

I am a seasoned professional with extensive experience spanning over two decades in the pharmaceutical and healthcare industries. Previously, I served as the Global Head of Evidence Synthesis, Modeling and Market Access Communications at a major global consultancy, where I was instrumental in driving strategic initiatives, uniting three business units, and driving financial success.  

Before that, I held leadership positions at various major international consultancies, honing my expertise in market access, pricing and reimbursement. With a background in health economics and business development, I have consistently contributed to the advancement of healthcare solutions throughout my career.  

I’m proud to be based out of London in the United Kingdom and hold multiple postgraduate degrees from various UK and European universities.  

What are your top priorities within your first 90 days? 

My top imperative is to establish EVERSANA in Europe as a major consultancy for value and access by hiring incredible talent and delighting clients. If you or someone you know is interested in taking the next step in their career and are based in Europe, I encourage you to keep an eye on our open roles.  

Pamela Vo, VP, HEOR Focuses on Improving Patient Lives from Basel, Switzerland

What expertise do you bring to the team?

With over 18 years of HEOR experience in the pharma industry, I have a demonstrated history of strategically turning ideas into impactful results with a proven track record of peer-reviewed publications, substantial market access and reimbursement successes, regulatory approvals and clinical product adoption. I have worked across the full product lifecycle in multiple therapeutic areas in the U.S., as well as international settings. Most recently, I served as the Global HEOR & Access Evidence, Executive Director, at Novartis.  

Prior roles include Worldwide HEOR Director within the Global Patient Access division at Novartis and other leadership roles at Lundbeck and Abbott/AbbVie where I managed diverse portfolios in healthcare.  

I hold a Doctor of Pharmacy degree, as well as a Master of Pharmacoeconomics and Policy degree. Recently, I also obtained certification in Immuno-Oncology from Harvard Medical School HMX Pro. I am currently based in Switzerland and looking forward to expanding EVERSANA’s scientific expertise in Europe, U.S. and the rest of the world. 

What excites you most about joining the EVERSANA team? 

By joining EVERSANA, I will be part of an elite team dedicated to improving patients’ lives. This will be through generations of robust evidence that will help increase access to healthcare technologies, shape the healthcare landscape and strengthen EVERSANA’s contributions towards a better tomorrow for people worldwide. 

A focus on diversity, along with their therapeutic and technical expertise and strong global network, are additional reasons why I am thrilled to become part of the EVERSANA team.   

Deepika Thakur, Senior Director, HEOR Grows Canadian Presence 

What expertise do you bring to the team?

As an accomplished professional with experience in the healthcare industry, I am thrilled to join a warm and talented team of experts. With over a decade of experience, including roles within both industry and healthcare economic consulting firms, I specialize in evidence synthesis and health economic outcomes. 

Throughout my career, I have worked with internal and external stakeholders and demonstrated expertise in customer engagement, oversight of multi-faceted projects, and creative problem-solving. I’ve contributed to complex decision-making and strategic planning, notably contributing to the development of market access integrated disease and product strategy at Novartis, supporting the launch of several products.  

I’ve built, led and mentored teams and served as a jury member for research presentation awards. My dedication to driving positive outcomes in health research is fueled by a commitment to excellence and effective communication. 

I am currently based in Toronto, Canada, and hold a Master of Pharmacy (Pharmaceutical Chemistry) degree. 

Why did you choose to continue your career at EVERSANA?  

I have been a part of the Value & Evidence team for close to three months now and am particularly drawn to EVERSANA’s pragmatic vision and commitment to advancing life sciences services with the primary goal of a healthier world for all and improving the lives of patients.  

EVERSANA comprises a broad team of talented and innovative thinkers with a positive attitude toward problem-solving and designing creative solutions. The team has a great culture with an emphasis on inclusion, collaboration, continuous learning and growth. EVERSANA’s values align with my own personal and professional values, and being a part of EVERSANA helps me to realize how much I can contribute to positively impacting the lives of patients.